The clinical trial NCT00524303 conducted in 100 women with invasive BC overexpressing HER2, evaluated the effect of LPT in combination with standard neoadjuvant chemotherapy (5FU, Epirubicin, Cyclophosphamide, and PTX). Here, ERBB2 is linked to breast cancer.